<DOC>
	<DOCNO>NCT03005275</DOCNO>
	<brief_summary>In polycystic ovary syndrome ( PCOS ) patient , vitro maturation ( IVM ) intra-cytoplasmic sperm injection ( ICSI ) indicate optional treatment . Although recently ICSI technique report successful IVM achieve pregnancy , also become much expensive couple involve . Whilst high-income country offer Assisted Reproductive Technology ( ART ) procedures fully partially paid government , patient low middle-income country cover self-fund infertility treatment . With limited resource , study conduct base prevalence - base cost - effectiveness analysis necessary health manager , policy maker especially assist patient ' decision making country . However , still limit publish study evaluate cost-effectiveness strategy available literature . This study conduct base prevalence - base cost - effectiveness analysis patient 's perspective . Activity - base cost method use cost level healthcare system , patient pay directly indirectly . It also analyse incremental cost - effectiveness evaluate cost - effectiveness IVM ICSI PCOS woman .</brief_summary>
	<brief_title>A Comparison Cost - Effectiveness Stimulated ICSI IVM Strategy PCOS Women</brief_title>
	<detailed_description>A Cost - Effectiveness Analysis ( CEA ) Study : - To identify , measure , evaluate cost ICSI treatment IVM treatment PCOS patient , incremental cost ICSI system implement PCOS patient . - To quantify effectiveness ICSI treatment IVM number proportion clinical pregnancy , live birth , incremental effectiveness ICSI treatment implement PCOS patient . - To determine cost - effectiveness ICSI treatment compare IVM PCOS patient . - To measure incremental cost - effectiveness ICSI treatment implement . The sample size study 140 subject , group , treat 1 IVM ICSI cycle base upon cost effectiveness ( live birth rate ) . METHODS Cost - Effectiveness Analysis ( CEA ) Activity - base cost method use cost level healthcare system patient pay directly indirectly IVM ICSI . This study also analyze incremental cost - effectiveness evaluate cost - effectiveness ICSI treatment implement PCOS patient . Sensitivity analysis In study , two technique sensitivity analysis employ decision tree model , mention , one - way sensitivity analysis Probabilistic Sensitivity Analysis ( PSA ) . One - way sensitivity analysis Tornado diagram analyse Probability sensitivity analysis Monte Carlo simulation Scatter plot difference cost respect difference live birth gain analyse parameter vary together simultaneously . This study also provide cost - effectiveness acceptability curve ( CEAC ) . The CEAC apply probability sensitivity analysis result , base willingness pay ( WTP ) . This technique assess probability cost effective ICSI treatment compare IVM treatment , respect WTP . Study Setting : My Duc Hospital Type data : This study use retrospective secondary data collection . Interventions : IVM : - Day 2-4 : Ultrasound Antral Follicles Counts ( AFC ) . - FSH injection : Day 9 , 10 11 ( adjust 1-3 day avoid Ultrasound OPU holiday ) . Dose : normally 100 IU/day ( maybe 75 - 150 IU/day ) . - Follicle endometrium evaluate : day final injection one day later . - Cancel cycle , pregnancy detect suspected ovulation ultrasound . - hCG 10.000 IU : one day final FSH injection , 9 p.m. Can adjust HCG injection day ( ± 1-2 day ) avoid Ultrasound OPU vacation . - OPU : 1,5 day hCG injection ( normally 36-42 hour later ) . - Sperm collection : OPU day ( mature follicle present ) 1 day OPU day . - Embryo transfer : 3 day OPU . - Luteal support : progesterone gel ( 90 mg daily ) intra-vaginally estradiol ( 4 mg/day PO , twice daily ) initiate day OPU day thereafter . ICSI : Daily SC injection rFSH - recombinant follicle stimulate hormone ( minimum start dose around 150 IUI ) start On day 2 day 3 menstrual cycle ( Stimulation Day 1 ) continue include Stimulation Day 7 . From Stimulation Day 8 onwards , subject ICSI treatment group continue daily SC dose rFSH day Gonadotrophin-releasing hormone ( GnRH ) agonist day . The maximum rFSH dose continue treatment first 7 day 300 IU dose could adjust desire . To prevent premature luteinizing hormone ( LH ) surge GnRH antagonist ( ganirelix acetate SC 0.25 mg/ 0.5 mL ) administer start stimulation day 5 . If follicle ≥ 11mm visible USS Stimulation day 8 , embryo transfer cycle cancel . If ovarian response high risk Ovarian hyperstimulation syndrome ( OHSS ) , ( 30 follicle ≥ 11mm USS ) , rec-hCG require withheld , treatment cycle cancel . As soon three follicle 17mm observe USS least , GnRH agonist ( Triptorelin 0.2 mg ) use final oocyte maturation day . About 34-36 h thereafter , OPU follow ICSI perform . Two day oocyte pick-up 2 fresh embryo transfer . Patients high progesterone level trigger day ( progesterone level &gt; 2ng/ml ) , freeze recommend . Patients use GnRH agonist fresh transfer intense luteal phase support E2 P4 ( receive intense luteal phase support E2 P4 dose mention progesterone 50 mg i.m . /day ) , unless patient high progesterone level day trigger ( progesterone level &gt; 2ng/ml ) , freeze recommend . Frozen embryo transfer cycle : - Time starting : - Day 2-4 cycle . - When start use drug , endometrial thickness ≤ 9mm . - Drugs - Estradiol valerate ( Valiera 2mg , Progynova 2mg ) . - Starting dose : 8mg/day ( Valiera 2mg per o , four time , daily ) 6 day . - Adjusting dose : - Increasing 12mg/day ( Valiera 2mg per o , three time per day , every time 02 tablet ) 5 day EM thickness &lt; 10mm 6 day use 8mg/day . - Increasing 16 mg/day ( Valiera 2mg per o , four time , every time 2 tablet ) 4 day EM thickness &lt; 10mm 5 day use 12mg/day . - Attention : Dose 16mg/day , patient must perform ultrasound every 3-4 day detect side effect ( headache , dizzy ) . When side effect happen , stop regimen . - Maximum treatment interval 28 day . - Decide transfer : - Endometrium thickness ( EM ) ≥ 8mm ( standard n't apply patient ) . - The minimum time use estradiol valerate : 10 day . - Drug : - Progesterone per vagina : - Cyclogest 400mg , tid pv , 01 tablet , 16 day . - Crinone 8 % gel , tid pv , 01tube . - Estradiol valerate : - Valiera 2mg , four time per o , 01 tablet 16 day . - The day Embryo transfer depend age embryo ( Day 2 , 3 , 5 ) . Assessments Before start ovarian stimulation , pregnancy exclude mean hCG test , blood sample obtain hormone assessment , USS perform measure count visible follicle . Patients return clinic USS blood sample stimulation day 5 8 , day hCG GnRH agonist administration . Additional blood sample collect day embryo transfer 2 week embryo transfer . Recruitment : Chief investigator ( CI ) review medical record collect data ( cost , effectiveness , epidemic characteristic ... ) , contact PCOS patient . Then CI colleague call patient invite participate project provide information study . If agree take part , collect data indirect cost ( transportation , administrative cost ... ) provide . The patient right withdraw study time . ETHICAL CONSIDERATIONS Institutional Review Board My Duc Hospital review study . The main ethical concern whether research place patient undue risk whether subject fully inform nature study . The study conduct Ethics Committee approval grant . Ethics approval - From My Duc Hospital Confidentiality - Information sheet de-identified . A unique number give participant . Master list hold CI separately data . Declaration interest - None Access data - Investigators Ancillary post-trial care - None</detailed_description>
	<mesh_term>Infertility</mesh_term>
	<mesh_term>Deslorelin</mesh_term>
	<criteria>Include : Couples undergo IVM ICSI treatment 1st time . Husband : total mobile sperm count 10 million/ml ( wash ) 2 million/ml ( wash ) normal semen analysis ( WHO 2010 criterion ) . Wife : PCOS patient ( Rotterdam European Society Human Reproduction Embryology ( ESHRE ) / American Society Reproductive Medicine ( ASRM ) 2004 age 18 37 time conduct IVM ICSI . Each subject must result clinical laboratory test ( complete blood count ( CBC ) , blood chemistry , urinalysis , pap smear ) within normal limit clinically acceptable investigator , measure local laboratory screening . Each subject must result physical examination , include blood pressure , within normal limit clinically acceptable limit investigator . Exclude : The subject ( wife ) recent ( i.e . within 3 year prior conduct IVM ICSI ) history of/ current endocrine abnormality ( irrespective whether patient stabilize treatment ) . The subject recent history of/or current epilepsy , thrombophilia , diabetes , cardiovascular , gastrointestinal , hepatic , renal pulmonary autoimmune disease require regular treatment . Endometriosis ( uterine muscle , ovary pelvis ) IVF/ICSI donate sperm , donate egg IVM donate sperm , clomiphene citrate resistant PCOS ( PCOS ) , tubal factor ( blocked fallopian tube , hydrosalpinx ) , abnormal uterine structure ( submucosal fibroid intramural fibroid ≥30 mm , uterine polyp , bicornuate uterus , didelphic uterus ) . The subject test positive Human Immunodeficiency Virus ( HIV ) Hepatitis B ( local laboratory ; result obtain within one year prior conduct IVM ICSI consider valid ) . The subject contraindication use gonadotropin ( ex ; tumor , pregnancy/lactation , undiagnosed vaginal bleeding , hypersensitivity , ovarian cyst ) GnRHantagonist ( e.g . hypersensitivity , pregnancy/lactation ) . The subject know gene defect , genetic abnormality , abnormal karyotyping , relevant current indication health offspring . The subject smoke recently stop smoking ( ex . within last 3 month ) . The subject history presence alcohol drug abuse within 12 month prior conduct IVM ICSI . The subject use experimental drug within 3 month prior conduct IVM ICSI . The subject participate clinical study ( exclude survey ) . Those complete process IVM IVF/ICSI ( withdraw , embryo transfer embryos n't transfer ) .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>37 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>